DOJ Lawsuit Against Modern Vascular Lacks Merit
Phoenix, Arizona, Dec. 27, 2022 (GLOBE NEWSWIRE) -- After more than two years of investigating Modern Vascular based on qui...
Month: December 2022
Minerva Surgical Announces $30 Million Private Placement of Common Stock Led by Accelmed Partners
SANTA CLARA, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a...
Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) – Interim Results for the Six Months Ended 30 June 2022
Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet needLONDON, Dec. 27, 2022...
Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics
-- Agreement Covers Buyout of Remaining Financial Obligations for Anti-CCR8 Antibody in Development as a Potential Treatment for Solid Tumors...
Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference
SEATTLE, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that...
Seer to Present at the J.P. Morgan 41st Annual Health Care Conference
REDWOOD CITY, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive...
SeaSpine Announces 100th Placement of 7D FLASH™ Navigation System
CARLSBAD, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on...
Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg
Primary endpoint of time to substantial symptom resolution was not met in acutely symptomatic, non-hospitalized COVID-19 patientsCNM-ZnAg treatment was safe...
Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED
-- On-track to initiate Phase 2b trial in 1Q 2023; Topline data expected in 1Q 2024 -- -- Received remaining $25...
Masitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in Switzerland
PRESS RELEASE MASITINIB RECEIVES ORPHAN DRUG STATUS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN SWITZERLAND Paris, December 27,...
Modern Vascular and Local Interventional Radiologist Pair Up To Reduce Unnecessary Amputations in Houston, Texas
HOUSTON, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Modern Vascular, the national leader in minimally invasive treatment for Peripheral Artery Disease...
Smart for Life Announces Launch of Greens First Protein Bars
New Line of Protein Bars Specifically Formulated with the Greens First PRO Line, Provides a Nutrient Dense Meal Replacement with...
SI-BONE, Inc. Announces FDA Clearance for Expanded Rod Compatibility with the iFuse Bedrock Granite® Implant System
New Indications Include Use with a Broad Class of Commercially Available Rods iFuse Bedrock Granite® iFuse Bedrock Granite® SANTA CLARA,...
Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders
New FDA-approved formulation for patients living with urea cycle disorders $42.5 million of non-dilutive debt funding available to Acer that,...
ALR Technologies Announces Sales Guidance for Q4 2022, Q1 2023, and Completion of the GluCurve Pet CGM Manufacturing Agreement
SINGAPORE, Dec. 27, 2022 (GLOBE NEWSWIRE) -- ALR Technologies SG Ltd. (“ALRT”) (OTCQB:ALRTF), the diabetes management company, today announced the...
TRACON Pharmaceuticals Announces up to $30M Non-Recourse Non-Dilutive Financing Related to Arbitration Award Decision Expected in Q1 2023
Initial $3.5M Funding Maintains Cash Runway of Mid-2023SAN DIEGO, Dec. 27, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a...
Acerus Announces Resignation of Director
TORONTO, Dec. 26, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced...
Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region
SHANGHAI, China, Dec. 26, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a...
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
- FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on...
Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
- FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on...